# Grace Therapeutics, Inc.: financial statements, quarterly

GRCE · Nasdaq · CIK 1444192 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/grce.md) · [Financials](/companies/grce/financials.md) · [Filings](/companies/grce/filings.md) · [Insiders](/companies/grce/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/grce/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [0.5](/filings/0001140361-24-046312.md) | [1.4](/filings/0001140361-25-004153.md) | [1.7 d](/filings/0001140361-25-023259.md) | [2.7](/filings/0001140361-25-030398.md) | [3.0](/filings/0001140361-25-041804.md) | [2.2](/filings/0001140361-26-004924.md) | [1.6 d](/filings/0001140361-26-025662.md) | [1.0](/filings/0001140361-26-032632.md) | [0.6](/filings/0001140361-25-041804.md) | [0.5](/filings/0001140361-26-004924.md) | [0.4 d](/filings/0001140361-26-025662.md) | [0.7](/filings/0001140361-26-032632.md) |
| Operating income | $m | [(2.1)](/filings/0001140361-24-046312.md) | [(3.0)](/filings/0001140361-25-004153.md) | [(3.3) d](/filings/0001140361-25-023259.md) | [(5.0)](/filings/0001140361-25-030398.md) | [(4.8)](/filings/0001140361-25-041804.md) | [(3.7)](/filings/0001140361-26-004924.md) | [(3.2) d](/filings/0001140361-26-025662.md) | [(3.1)](/filings/0001140361-26-032632.md) | [(2.5)](/filings/0001140361-25-041804.md) | [(2.4)](/filings/0001140361-26-004924.md) | [(3.0) d](/filings/0001140361-26-025662.md) | [(15.9)](/filings/0001140361-26-032632.md) |
| Income tax | $m | [(0.4)](/filings/0001140361-24-046312.md) | [(0.2)](/filings/0001140361-25-004153.md) | [(0.9) d](/filings/0001140361-25-023259.md) | [(0.7)](/filings/0001140361-25-030398.md) | [(0.9)](/filings/0001140361-25-041804.md) | [(0.6)](/filings/0001140361-26-004924.md) | [(1.0) d](/filings/0001140361-26-025662.md) | [0.0](/filings/0001140361-26-032632.md) | [0.0](/filings/0001140361-25-041804.md) | [0.0](/filings/0001140361-26-004924.md) | [(1.7) d](/filings/0001140361-26-025662.md) | [0.0](/filings/0001140361-26-032632.md) |
| Net income | $m | [(3.3)](/filings/0001140361-24-046312.md) | [(2.4)](/filings/0001140361-25-004153.md) | [(3.2) d](/filings/0001140361-25-023259.md) | [(2.6)](/filings/0001140361-26-004924.md) | [(3.4)](/filings/0001140361-26-004924.md) | [(4.2)](/filings/0001140361-26-004924.md) | [0.6 d](/filings/0001140361-26-025662.md) | [(3.4)](/filings/0001140361-26-032632.md) | [(0.9)](/filings/0001140361-26-004924.md) | [(2.3)](/filings/0001140361-26-004924.md) | [(1.2) d](/filings/0001140361-26-025662.md) | [(15.8)](/filings/0001140361-26-032632.md) |
| Diluted EPS | $ per share | [(0.43)](/filings/0001140361-24-046312.md) | [(0.21)](/filings/0001140361-25-004153.md) | not reported | [(0.24)](/filings/0001140361-25-030398.md) | [(0.30)](/filings/0001140361-25-041804.md) | [(0.36)](/filings/0001140361-26-004924.md) | not reported | [(0.21)](/filings/0001140361-26-032632.md) | [(0.06)](/filings/0001140361-25-041804.md) | [(0.14)](/filings/0001140361-26-004924.md) | not reported | [(0.91)](/filings/0001140361-26-032632.md) |
| Basic EPS | $ per share | [(0.43)](/filings/0001140361-24-046312.md) | [(0.21)](/filings/0001140361-25-004153.md) | not reported | [(0.24)](/filings/0001140361-25-030398.md) | [(0.30)](/filings/0001140361-25-041804.md) | [(0.36)](/filings/0001140361-26-004924.md) | not reported | [(0.21)](/filings/0001140361-26-032632.md) | [(0.06)](/filings/0001140361-25-041804.md) | [(0.14)](/filings/0001140361-26-004924.md) | not reported | [(0.91)](/filings/0001140361-26-032632.md) |

- Revenue: not reported
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [27.0](/filings/0000950170-23-062437.md) | [18.5](/filings/0000950170-24-013566.md) | [23.0](/filings/0001140361-25-023259.md) | [19.4](/filings/0000950170-24-094348.md) | [15.2](/filings/0001140361-24-046312.md) | [11.1](/filings/0001140361-25-004153.md) | [22.1](/filings/0001140361-26-025662.md) | [20.0](/filings/0001140361-25-030398.md) | [16.9](/filings/0001140361-25-041804.md) | [18.7](/filings/0001140361-26-004924.md) | [17.0](/filings/0001140361-26-032632.md) | [13.8](/filings/0001140361-26-032632.md) |
| Current assets | $m | [28.9](/filings/0000950170-23-062437.md) | [26.9](/filings/0000950170-24-013566.md) | [24.0](/filings/0001140361-25-023259.md) | [20.4](/filings/0000950170-24-094348.md) | [16.1](/filings/0001140361-24-046312.md) | [11.9](/filings/0001140361-25-004153.md) | [22.7](/filings/0001140361-26-025662.md) | [20.5](/filings/0001140361-25-030398.md) | [17.3](/filings/0001140361-25-041804.md) | [19.2](/filings/0001140361-26-004924.md) | [17.4](/filings/0001140361-26-032632.md) | [14.3](/filings/0001140361-26-032632.md) |
| Total assets | $m | [78.2](/filings/0000950170-23-062437.md) | [76.2](/filings/0000950170-24-013566.md) | [73.3](/filings/0001140361-25-023259.md) | [69.7](/filings/0000950170-24-094348.md) | [65.3](/filings/0001140361-24-046312.md) | [61.2](/filings/0001140361-25-004153.md) | [72.0](/filings/0001140361-26-025662.md) | [69.8](/filings/0001140361-25-030398.md) | [66.6](/filings/0001140361-25-041804.md) | [68.5](/filings/0001140361-26-004924.md) | [66.7](/filings/0001140361-26-032632.md) | [50.1](/filings/0001140361-26-032632.md) |
| Current liabilities | $m | [1.4](/filings/0000950170-23-062437.md) | [1.8](/filings/0000950170-24-013566.md) | [1.7](/filings/0001140361-25-023259.md) | [2.6](/filings/0000950170-24-094348.md) | [2.7](/filings/0001140361-24-046312.md) | [2.0](/filings/0001140361-25-004153.md) | [1.9](/filings/0001140361-26-025662.md) | [2.3](/filings/0001140361-25-030398.md) | [1.2](/filings/0001140361-25-041804.md) | [1.3](/filings/0001140361-26-004924.md) | [2.1](/filings/0001140361-26-032632.md) | [1.3](/filings/0001140361-26-032632.md) |
| Total liabilities | $m | [11.5](/filings/0000950170-23-062437.md) | [11.5](/filings/0000950170-24-013566.md) | [11.6](/filings/0001140361-25-023259.md) | [10.4](/filings/0000950170-24-094348.md) | [9.2](/filings/0001140361-24-046312.md) | [9.1](/filings/0001140361-25-004153.md) | [5.4](/filings/0001140361-26-025662.md) | [6.3](/filings/0001140361-25-030398.md) | [3.8](/filings/0001140361-25-041804.md) | [3.6](/filings/0001140361-26-004924.md) | [2.8](/filings/0001140361-26-032632.md) | [1.9](/filings/0001140361-26-032632.md) |
| Shareholders' equity | $m | [66.7](/filings/0001140361-25-004153.md) | [64.7](/filings/0001140361-25-004153.md) | [61.7](/filings/0001140361-26-025662.md) | [59.4](/filings/0001140361-26-004924.md) | [56.1](/filings/0001140361-26-004924.md) | [52.1](/filings/0001140361-26-004924.md) | [66.6](/filings/0001140361-26-032632.md) | [63.6](/filings/0001140361-26-032632.md) | [62.8](/filings/0001140361-26-004924.md) | [64.9](/filings/0001140361-26-004924.md) | [63.9](/filings/0001140361-26-032632.md) | [48.2](/filings/0001140361-26-032632.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,113) d](/filings/0001140361-24-046312.md) | [(1,892) d](/filings/0001140361-25-004153.md) | [(2,088) d](/filings/0001140361-25-023259.md) | [(3,596)](/filings/0001140361-25-030398.md) | [(4,239) d](/filings/0001140361-25-041804.md) | [(4,115) d](/filings/0001140361-26-004924.md) | [(2,954) d](/filings/0001140361-26-025662.md) | [(1,801)](/filings/0001140361-26-032632.md) | [(3,143) d](/filings/0001140361-25-041804.md) | [(2,230) d](/filings/0001140361-26-004924.md) | [(1,695) d](/filings/0001140361-26-025662.md) | [(3,221)](/filings/0001140361-26-032632.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [7.4](/filings/0000950170-23-062437.md) | [7.4](/filings/0000950170-24-013566.md) | [7.4](/filings/0000950170-24-094348.md) | [7.6](/filings/0001140361-24-046312.md) | [11.5](/filings/0001140361-25-004153.md) | [10.9](/filings/0001140361-25-030398.md) | [11.5](/filings/0001140361-25-041804.md) | [11.5](/filings/0001140361-26-004924.md) | [15.9](/filings/0001140361-26-032632.md) | [15.9](/filings/0001140361-25-041804.md) | [16.9](/filings/0001140361-26-004924.md) | [17.3](/filings/0001140361-26-032632.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 21,035,930 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001140361-26-032632.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.